Trial reportMucosal immunology2017
Agglutination by anti-capsular polysaccharide antibody is associated with protection against experimental human pneumococcal carriage.
Trial report in Mucosal immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 101 citations in OpenAlex.
- Sustained salivary IgG but short-lived IgA responses following primary and booster MenACWY-TT vaccination in older adults.Human vaccines & immunotherapeutics · 2026Trial
- Effect of colonisation with Neisseria lactamica on cross-reactive anti-meningococcal B-cell responses: a randomised, controlled, human infection trial.The Lancet. Microbe · 2022Trial
- Pneumococcal colonization impairs mucosal immune responses to live attenuated influenza vaccine.JCI insight · 2021Trial
- Innate and adaptive nasal mucosal immune responses following experimental human pneumococcal colonization.The Journal of clinical investigation · 2019Trial
- Trial
- Trial
- Bacterial and host factors affecting acquisition ofInfection and immunity · 2026Article
- Induction of Salivary IgA and IgG Responses by Parenteral PPV23 Vaccination in Older Adults.Open forum infectious diseases · 2026Article
- Pooled analysis of PCV13 efficacy from controlled human infection trials in Malawi and the UK.NPJ vaccines · 2026Article
- Bacterial and host factors affecting acquisition ofbioRxiv : the preprint server for biology · 2026Article
- Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review.Human vaccines & immunotherapeutics · 2025Review
- Article
- Serotype 3 Streptococcus pneumoniae Escapes the Immune Responses Induced by PCV13 in Mice With High Susceptibility to Infection.Immunity, inflammation and disease · 2024Article
- Inflammation of the nasal mucosa is associated with susceptibility to experimental pneumococcal challenge in older adults.Mucosal immunology · 2024Article
- Article
- Inhaled Corticosteroids Is Not Associated with the Risk of Pneumonia in Asthma.Tuberculosis and respiratory diseases · 2023Article
- Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data.EClinicalMedicine · 2023Article
- Influence of glycan structure on the colonization ofProceedings of the National Academy of Sciences of the United States of America · 2023Article
- A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein mediates immune function.EMBO molecular medicine · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 4 countries.
Funding
Abstract
The ability of pneumococcal conjugate vaccine (PCV) to decrease transmission by blocking the acquisition of colonization has been attributed to herd immunity. We describe the role of mucosal immunoglobulin G (IgG) to capsular polysaccharide (CPS) in mediating protection from carriage, translating our findings from a murine model to humans. We used a flow cytometric assay to quantify antibody-mediated agglutination demonstrating that hyperimmune sera generated against an unencapsulated mutant was poorly agglutinating. Passive immunization with this antiserum was ineffective to block acquisition of colonization compared to agglutinating antisera raised against the encapsulated parent strain. In the human challenge model, samples were collected from PCV and control-vaccinated adults. In PCV-vaccinated subjects, IgG levels to CPS were increased in serum and nasal wash (NW). IgG to the inoculated strain CPS dropped in NW samples after inoculation suggesting its sequestration by colonizing pneumococci. In post-vaccination NW samples pneumococci were heavily agglutinated compared with pre-vaccination samples in subjects protected against carriage. Our results indicate that pneumococcal agglutination mediated by CPS-specific antibodies is a key mechanism of protection against acquisition of carriage. Capsule may be the only vaccine target that can elicit strong agglutinating antibody responses, leading to protection against carriage acquisition and generation of herd immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.